Blog - Page 342 of 5639 - QualityStocks

WednesdayJan 08, 2025 2:22 pm

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALS

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). The company recently secured a new $10 million debt facility, which enables the payoff of another higher interest rate loan and the finance of operations to generate additional data to support the new drug application of lead drug candidate CNM-Au8 for ALS. “We believe that the proceeds from this new debt facility, including an extended interest-only period, will allow Clene the cash…

WednesdayJan 08, 2025 12:30 pm

QualityStocksNewsBreaks – MoneyShow’s Virtual Event to Showcase Actionable Insights, Strategic Investment Playbook

MoneyShow, a leading producer of financial conferences for investors, traders and advisors, today announced the upcoming “Your 2025 Portfolio Playbook Virtual Expo” set to take place on Jan. 28-29, 2025. The fully virtual event will showcase more than 30 renowned speakers and feature world-class educational opportunities, with a focus on crafting a profitable investment strategy for 2025 and beyond. “With policy uncertainty, inflationary pressures and geopolitical instability affecting markets, this event provides sharp and actionable insights from elite financial experts,” said Mike Larson, editor-in-chief at MoneyShow. “Attendees will leave with a comprehensive playbook to navigate unpredictable financial currents and capitalize…

WednesdayJan 08, 2025 9:30 am

Israel Announces New Hub to Expedite Military AI and Autonomy Research

The government in Israel has set up a new office based at the Defense Ministry. This office will superintend over the development of technology focused on AI and autonomy. Dubbed the AI & Autonomy Administration, this team will operate under the auspices of the ministry’s defense research and development directorate. The directorate plays a crucial role in Israel’s military technology space. Officials revealed that the purpose of this new office is to revolutionize the war capabilities of every section of the military so that the IDF (Israel Defense Forces) maintains its operational superiority within the region. The office will bring…

WednesdayJan 08, 2025 9:25 am

QualityStocksNewsBreaks – Sekur Private Data Ltd. (CSE: SKUR) (OTCQX: SWISF) (FSE: GDT0) with Code4Cybersecurity to Offer Swiss-Hosted Privacy Solutions

Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FSE: GDT0) announced a partnership with Code4Cybersecurity LLC to distribute its Swiss-hosted privacy and secure communication solutions, including SekurMail, SekurMessenger, and SekurVPN, to Code4’s network of corporate entities, high-net-worth individuals, and entertainment industry VIPs. The collaboration supports Sekur’s strategy of expanding its reach through B2B partnerships and emphasizes its commitment to data security under Switzerland’s strict Federal Act on Data Protection. Sekur’s solutions, designed to counter mass surveillance and enhance user privacy, are offered in two packages: PRIVACY at $25/month or $275/year and PRIVACY+ at $65/month. Code4 CEO Raffi Pamboukian and Sekur CEO…

WednesdayJan 08, 2025 8:45 am

Adageis, at the Forefront of AI-Driven Transformation in Healthcare

AI promises to revolutionize patient care by improving efficiency, reducing costs and enabling value-based care models. AI-driven risk engines enable providers to pinpoint high-risk patients and proactively address health issues. Combining advanced AI-driven analytics with flexible EHR integration through its ProActive Care Platform, Adageis helps providers meet revenue and care quality metrics in a value-driven healthcare landscape. The Adageis platform facilitates real-time patient oversight, improving outcomes beyond traditional visits. Artificial intelligence is rapidly reshaping healthcare by enabling precision medicine, predictive analytics and operational efficiency. As the industry transitions toward value-based care, AI plays a crucial role in meeting quality metrics,…

WednesdayJan 08, 2025 8:00 am

SolarBank Corp. (NASDAQ: SUUN) (CSE: SUNN) Is ‘One to Watch’

SolarBank has a development pipeline exceeding 1 GW, with over 100 MW of renewable energy projects completed. The company operates a vertically integrated business model, ensuring cost efficiency and maximizing profitability across the project lifecycle. SolarBank recently secured a $25.8 million project finance facility for two BESS projects, demonstrating robust financial backing. Announced expansion into the rapidly growing data center market positions the company to tap into an industry that’s forecast to reach a value of $395 billion by 2030. Leadership with over 100 years of combined experience ensures strong operational expertise and strategic vision. SolarBank’s diverse portfolio spans solar…

TuesdayJan 07, 2025 2:15 pm

QualityStocksNewsBreaks – ROTH Expands Team to Continue Driving Innovation in Tech Space

Roth Capital Partners, LLC (“ROTH”) today announced the expansion of its technology team with the addition of Marc Lewis as Managing Director, Head of Technology Investment Banking, and Imtiaz (“Taz”) Koujalgi as Managing Director, Senior Research Analyst, specializing in Enterprise Software. The appointments reinforce ROTH’s commitment to support innovation and growth in the dynamic and rapidly evolving technology sector. “We are pleased to welcome Marc and Taz to the ROTH team as we continue to expand our presence in the rapidly evolving technology sector,” said ROTH’s President and Head of Investment Banking, Aaron Gurewitz. “Marc’s extensive investment banking and portfolio…

TuesdayJan 07, 2025 1:46 pm

QualityStocksNewsBreaks – SolarBank Corp. (NASDAQ: SUUN) (CSE: SUNN) (NEO: SUNN) (FSE: GY2) Secures $25.8M Finance Facility

SolarBank (NASDAQ: SUUN) (CSE: SUNN) (NEO: SUNN) (FSE: GY2) announced that its subsidiary has secured the financial closing of a combined project loan in a principal amount of $25.8 million from Royal Bank of Canada. The loan will be used for the construction, operation and maintenance of two 4.99 MW Battery Energy Storage System (“BESS”) projects to be located in Ontario, with project names SFF 06 and 903, respectively. According to the announcement, the projects are owned by 1000234763 Ontario Inc., which is the borrower under the terms of the loan. The projects represent SolarBank's initial foray into battery energy…

TuesdayJan 07, 2025 1:30 pm

QualityStocksNewsBreaks – PSQ Holdings Inc. (NYSE: PSQH) Secures $36.2M in Registered Direct

PSQ Holdings (NYSE: PSQH) is America's leading commerce and payments ecosystem valuing life, family and liberty. The company recently announced its entry into definitive agreements for the purchase and sale of an aggregate of 7,813,931 shares of its Class A common stock, each at a price of $4.63, in a registered direct offering for gross proceeds of approximately $36.2 million. Roth Capital Partners acted as sole placement agent for the offering. For more information, visit https://ibn.fm/fB7c7 About PublicSquare PublicSquare is America’s leading commerce and payments ecosystem, valuing life, family and liberty. PublicSquare operates under three segments: Marketplace, Financial Technology and…

TuesdayJan 07, 2025 1:10 pm

QualityStocksNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Streamlined Pathway to Advance Buntanetap for AD

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), today announced that the FDA has accepted an updated protocol for the pivotal Phase 3 AD study, which is slated to begin in January 2025. In October 2024, the FDA granted clearance for Annovis to proceed with the pivotal Phase 3 AD studies based on its Phase 2/3 data demonstrating cognitive improvement in early-stage AD patients. The original protocol design proposed two separate trials that are now integrated into a single 6/18-month trial under the…

Site Search

Company Search